EGFR and non-small cell lung carcinoma: To assess the activity of PD-1/PD-L1 inhibitors according to the molecular genotype of NSCLC, we reanalyzed the publicly available trial data (2018 MSKCC), focusing on patients with EGFR, KRAS, and ALK fusion mutations30.